Steven Cohen Corvus Pharmaceuticals, Inc. Put Options Transaction History

Point72 Asset Management, L.P.

  • $51 Billion
  • Q3 2025

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

About Corvus Pharmaceuticals, Inc.

CRVS Quotes by TradingView
  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $408M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email